AU2012209100A1 - Combinations - Google Patents

Combinations Download PDF

Info

Publication number
AU2012209100A1
AU2012209100A1 AU2012209100A AU2012209100A AU2012209100A1 AU 2012209100 A1 AU2012209100 A1 AU 2012209100A1 AU 2012209100 A AU2012209100 A AU 2012209100A AU 2012209100 A AU2012209100 A AU 2012209100A AU 2012209100 A1 AU2012209100 A1 AU 2012209100A1
Authority
AU
Australia
Prior art keywords
amino
compound
pharmaceutically acceptable
acceptable salt
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012209100A
Other languages
English (en)
Inventor
Kurt R. Auger
Justin BOTTSFORD-MILLER
Anil K. Sood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
The University of Texas System
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd, The University of Texas System, The University of Texas at Austin filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of AU2012209100A1 publication Critical patent/AU2012209100A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012209100A 2011-01-26 2012-01-26 Combinations Abandoned AU2012209100A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161436435P 2011-01-26 2011-01-26
US61/436,435 2011-01-26
PCT/US2012/022638 WO2012103276A1 (en) 2011-01-26 2012-01-26 Combinations

Publications (1)

Publication Number Publication Date
AU2012209100A1 true AU2012209100A1 (en) 2013-08-01

Family

ID=46581159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012209100A Abandoned AU2012209100A1 (en) 2011-01-26 2012-01-26 Combinations

Country Status (13)

Country Link
US (2) US20130296356A1 (enExample)
EP (1) EP2667871A4 (enExample)
JP (1) JP2014503589A (enExample)
KR (1) KR20140011322A (enExample)
CN (1) CN103476413B (enExample)
AU (1) AU2012209100A1 (enExample)
BR (1) BR112013018565A2 (enExample)
CA (1) CA2825790A1 (enExample)
EA (1) EA201391076A1 (enExample)
IL (1) IL227377A0 (enExample)
MX (1) MX2013008654A (enExample)
SG (1) SG191926A1 (enExample)
WO (1) WO2012103276A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
EP2906215A4 (en) * 2012-10-12 2016-05-18 SUITS
AU2013334945A1 (en) * 2012-10-22 2015-04-23 Novartis Ag Combination
US20150306099A1 (en) * 2012-11-27 2015-10-29 Glaxosmithkline Llc Combination
EP4578449A4 (en) * 2022-08-24 2026-01-21 Inxmed Nanjing Co Ltd PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND COMBINED USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034860B2 (en) * 2006-07-21 2011-10-11 Eastman Specialties Holdings Corporation Organosol plastisol compositions
EP2134689B1 (en) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
WO2010036796A1 (en) * 2008-09-26 2010-04-01 Concert Pharmaceuticals, Inc. Pyridineamine derivatives
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak

Also Published As

Publication number Publication date
US20160067248A1 (en) 2016-03-10
CN103476413B (zh) 2016-03-16
KR20140011322A (ko) 2014-01-28
BR112013018565A2 (pt) 2016-09-27
IL227377A0 (en) 2013-09-30
EA201391076A1 (ru) 2014-07-30
EP2667871A1 (en) 2013-12-04
MX2013008654A (es) 2013-09-02
SG191926A1 (en) 2013-08-30
US20130296356A1 (en) 2013-11-07
JP2014503589A (ja) 2014-02-13
WO2012103276A1 (en) 2012-08-02
CN103476413A (zh) 2013-12-25
CA2825790A1 (en) 2012-08-02
EP2667871A4 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
US20160067248A1 (en) Combinations
JP2008514577A (ja) Ｚｄ６４７４及びイマチニブを含んでなる組合せ
JP2008514576A (ja) Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
JP2013536243A (ja) 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
JP6546098B2 (ja) 組み合わせ処置
EP4196116B1 (en) Pharmaceutical composition comprising cabozantinib, plerixafor, afatinib and etoricoxib for use in the treatment or prophylaxis of nsclc without driver mutations
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
CA2610628A1 (en) Combination therapy
CA2531643A1 (en) Combination therapy
US20170027938A1 (en) Combination
MX2007016497A (es) Terapia de combinacion para cancer con azd2171 y gemcitabina.
EP2654754B1 (en) Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
JP2013526613A (ja) 組合せ
JP2015534987A (ja) 組合せ
WO2011152515A1 (ja) インドール化合物を含有する抗腫瘍剤
CN101027058A (zh) 包含azd2171和伊马替尼的癌症联合治疗
JP2014034535A (ja) Ｈｓｐ９０阻害剤とｖｅｇｆｒチロシンキナーゼ且つｐｄｇｆチロシンキナーゼ阻害剤の組み合わせ
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ
WO2011152516A1 (ja) キナーゼ阻害剤を組み合わせた抗腫瘍剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted